Motif Bio PLC - AIM cash shell - Continues to progress a reverse takeover with a UK-based antibody-drug conjugate discovery and development company. Motif looking to acquire the entire issued share capital of the target firm.
"Motif will remain suspended from trading while the proposed transaction is negotiated and advanced, and the company will provide shareholders with further updates as appropriate," company says.
"Many of the key work streams of the proposed transaction are now substantially complete. However, as a result of additional audit work which is required for the year ended December 31, 2020, marketing is now not expected to commence until the second half of April 2021. As such, should the proposed transaction proceed, it is expected that Motif will now publish the AIM admission document in late April or early May 2021."
Current stock price: 0.50 pence
Year-to-date change: suspended
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.


TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac


IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million


TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound


TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac


IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million


TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound


IN BRIEF: Motif Bio 2020 loss narrows due to impairment in prior year


IN BRIEF: Motif Bio progresses reverse takeover, expects AIM return


LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary


IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy


IN BRIEF: Motif Bio Advancing Process To Complete Reverse Takeover